Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nirmal, Jana"'
Autor:
Mahip K. Verma, Charudatt Samant, Ramesh Kale, Sukanya Patra, Nilesh Mahajan, Milind K. Gholve, Ajitkumar Marisetti, Brahmam Sunkara, Aditya Naik, Manisha Shingare, Madhusudhan Reddy, Anand M. Bokare, Atul Akarte, Sarita Koul, Prashant B. Nigade, Vinod B. Patil, Dipak Modi, Prajakta Ahirrao, Shashikant Pawar, Sandip Kuldharan, Lal Dinchhana, Maneesh Mehta, Jayasagar Gundu, Nirmal Jana, Prashant Vidhate, Sachin Jaysing Mahangare, Manojkumar R. Shukla, Rajan N. Goel, Mandar Bhonde, Rajender Kumar Kamboj, Venkata P. Palle
Publikováno v:
Biochemical and Biophysical Research Communications. 637:267-275
Phosphoinositide 3-kinase (PI3K) pathway mediates key signaling events downstream to B-cell receptor (BCR) for survival of mature B-cells, and overexpression or overactivation of PI3Kδ is crucial for B-cell malignancies such as diffuse large B-cell
Autor:
Anand Tarage, Gopal Gole, Mandar Bhonde, Madhusudhan Reddy, Sharad Sharma, Harish Volam, Sudeep Sabde, Sanjeev Anant Kulkarni, Sadanand Mallurwar, Brahmam Sunkara, Ramesh Dattatraya Phadtare, Manoj Dandekar, Hemant Goyal, Samiron Phukan, Gayathri Sadasivam, Rupesh Kanhere, Maneesh Mehta, Nirmal Jana, Murthy Cheemala, Prashant Vidhate, Lal Dinchhana, Prashant B. Nigade, Bernstein Peter Robert, Prajakta Ahirrao, Rajan Goel, Aditya Naik, Vipul Pachpute, Sukanya Patra, Rajender Kumar Kamboj, Nilesh Mahajan, Kaustubh Tamane, Sneha Trivedi, M. K. Singh, Ajit Kumar Marisetti, Shankar Bhagwat, Mahip Verma, Atul Akarte, Dipak Lagad, Charudatt Samant, Venkata P. Palle, Vinod Patil, Anand Bokare, Dipak Modi, Chaitanya A. Kulkarni, Lakshmi Narasimham, Neetinkumar Reddy, Majid Bashir Sayyed, Sarita Koul, Shukla Manojkumar Ramprasad, Milind Gholve, Swati Tota, Vinod D. Chaudhari, Jayasagar Gundu, Manisha Shingare, Sachin J Mahangare, Shashikant Pawar
Publikováno v:
Journal of Medicinal Chemistry. 63:14700-14723
PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness against at least one of the several important properties:
Autor:
Vijay Kanoje, Dilip Pandey, Akshaya Wagh, Sukanya Patra, Ajit Kumar Marisetti, Madhusudhan Reddy, Charudatt Samant, Nilesh Mahajan, Milind Gholve, Sudeep Sabde, Sneha Trivedi, Trupti Bhankhede, Vinod Patil, Prashant Nigade, Dipak Modi, Maneesh Mehta, Prajakta Ahirrao, Swathi Tota, Bidyut Nanda, Shashikant Pawar, Anuradha Polawar, Kaustubh Tamane, Sandip Kuldharan, Gururaj Vishwase, Nirmal Jana, Sachin J. Mahangare, Prashant Vidhate, Dipak Lagad, Jayasagar Gundu, Samiron Phukan, Manojkumar Shukla, Lakshmi Narasimham, Kumar V.S. Nemmani, Mandar Bhonde, Sharad Sharma, Rajender K. Kamboj, Venkata P. Palle
Publikováno v:
European Journal of Pharmacology. 927:175054
PI3Kδ plays a critical role in adaptive immune cell activation and function. Suppression of PI3Kδ has been shown to counter excessive triggering of immune responses which has led to delineating the role of this isoform in the pathophysiology of aut
Autor:
Manojkumar R, Shukla, Sukanya, Patra, Mahip, Verma, Gayathri, Sadasivam, Nirmal, Jana, Sachin J, Mahangare, Prashant, Vidhate, Dipak, Lagad, Anand, Tarage, Murthy, Cheemala, Chaitanya, Kulkarni, Shankar, Bhagwat, Vinod D, Chaudhari, Majid, Sayyed, Vipul, Pachpute, Ramesh, Phadtare, Gopal, Gole, Samiron, Phukan, Brahmam, Sunkara, Charudatt, Samant, Manisha, Shingare, Aditya, Naik, Sneha, Trivedi, Ajit Kumar, Marisetti, Madhusudhan, Reddy, Milind, Gholve, Nilesh, Mahajan, Sudeep, Sabde, Vinod, Patil, Dipak, Modi, Maneesh, Mehta, Prashant, Nigade, Kaustubh, Tamane, Swati, Tota, Hemant, Goyal, Harish, Volam, Shashikant, Pawar, Prajakta, Ahirrao, Lal, Dinchhana, Sadanand, Mallurwar, Atul, Akarte, Anand, Bokare, Rupesh, Kanhere, Neetinkumar, Reddy, Sarita, Koul, Manoj, Dandekar, Minakshi, Singh, Peter R, Bernstein, Lakshmi, Narasimham, Mandar, Bhonde, Jayasagar, Gundu, Rajan, Goel, Sanjeev, Kulkarni, Sharad, Sharma, Rajender Kumar, Kamboj, Venkata P, Palle
Publikováno v:
Journal of medicinal chemistry. 63(23)
PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness against at least one of the several important properties: